In this study, we developed a nonviral, cationic, targeted DNA-carrier system by coupling SAINT/DOPE lipids to monoclonal antibodies. The two monoclonal antibodies used were both tumor specific, that is, MOC31 recognizes the epithelial glycoprotein EGP-2 present in carcinomas and Herceptin recognizes the HER-2/neu protein in breast and ovarian cancers. Coupling was performed under nonreducing conditions by covalent attachment. The coupling procedure appeared to be reproducible and the binding capacity of the antibody was not affected by linking them to the cationic lipid. Binding and transfection efficiency was assayed with target cells and nontarget cells. SAINT/DOPE lipoplexes as such appeared to be an effective transfection reagent for various cell lines. After coupling SAINT/DOPE to the monoclonal antibodies or F(ab)2 fragments, it was shown that the targeted MoAb-SAINT/DOPE lipoplexes preferably bound to target cells, compared to binding to the nontarget cells, especially for the Herceptin-SAINT/DOPE lipoplexes. More importantly, transfection of the target cells could also be improved with these targeted lipoplexes. In conclusion, we have shown that by using monoclonal antibody-coupled SAINT/DOPE lipoplexes cells targeted gene delivery can be achieved, and also a higher number of transfected target cells was seen.
G ene therapy is a novel molecular approach designed to change or eliminate the cause of disease. The goal is to modify the genetic material of cells by introducing a therapeutic gene to treat or prevent disease. Efficacious therapy can be achieved by delivery of a specific DNA sequence to a tissue. The expression of the gene results in a protein that provides the beneficial effect, for instance by replacing a defective or a missing gene protein or by supplementing the body with new proteins in order to initiate an immune response. However, a barrier for the successful use of gene therapy is the ability to obtain efficient and specific gene delivery. 1 First, gene delivery was performed with viral vectors derived from retroviruses and adenoviruses that made use of the viral characteristics to deliver the gene into cells. [2] [3] [4] More recently, adeno-associated virus vectors are used (AAV) that have the ability to infect both dividing and nondividing cells. 5, 6 Still, the general disadvantages of viral vectors are the need for packaging cell lines for vector production, the limitations to the size of DNA that can be incorporated in the vector, and there is no targeting to certain cells. 3 Owing to the limitations of the viral vectors, nonviral vectors have been generated. The advantages of these vectors are that they can be manufactured synthetically to high purity and quality. Preparation does not involve biologically hazardous procedures as in viral production and they can be made from a wide array of components and thus may possess various properties. 7 The process of DNA binding is based on simple self-assembly through ionic interactions between the positive charge of the polycation's amine group and the negative charge of the DNA. Because charge neutralization is the basis for the polyplex formation, theoretically any nucleic acid of any size can be compacted. The resulting vector can range in size from as small as 10 nm to greater than 500 nm.
composed of a cationic lipid and a natural neutral phospholipid (i.e. dioleoylphosphatidylethanolamine (DOPE) in a 1 : 1 ratio that can bind DNA efficiently. This was first described for DOTMA/DOPE (called Lipofectin Felgner et al 13 ), and also DOTAP-based liposomes 14 and DOTIM-based liposomes 15 have been generated. Our aim is to develop a nonviral DNA carrier for in vivo application using SAINT as a cationic lipid. The application for this carrier will be in cancer patients where either a suicide gene can be introduced into the tumor that will kill specifically tumor cells or, on the other hand, an immunogenic gene can be introduced to enhance an immune response against tumor cells. SAINT (N-methyl-4(dioleyl)methylpyridinium chloride (SAINT-2)) is an amphiphilic lipid based on a pyridinium ring to which two alkyl chains are attached. [16] [17] [18] SAINT is used in a ratio of 1 : 1 with the neutral helper phospholipid DOPE. In this study, we have compared the in vitro transfection levels of SAINT/DOPE with other commercially available nonviral transfection reagents, that is, Fugene, Effectene, and Superfect.
An advantage of nonviral carriers is that they can be easily linked to a ligand in order to improve the targeted in vivo transfection efficiency of specific cells. To this end, transferrin has been used as a molecular conjugate to deliver DNA to erythroleukemic, lung, and liver cells. 7 Also, monoclonal antibodies and derivatives thereof can be used for targeting approaches. Some studies have proven that this can be an effective approach because higher transfection was seen in the cells recognized by the antibody. [19] [20] [21] [22] Because our aim is to target the lipoplex to tumor cells, we linked SAINT/DOPE chemically to the monoclonal antibodies MOC31 and Herceptin. MOC31 recognizes the tumor-associated antigen EGP-2.
23, 24 The Epithelial Glycoprotein 2 (EGP-2; also known as Ep-CAM) is a 38 kDa transmembrane glycoprotein with a distribution that is largely confined to human epithelial cells and their derived carcinomas. Herceptin is a humanized monoclonal antibody derived from 4D5 and recognizes the HER-2/neu protein, which is a proto-oncogene. 25, 26 HER-2/neu encodes a 185 kDa transmembrane receptor tyrosine kinase, which is overexpressed in 25-30% of human breast and ovarian cancers. After binding, the Herceptin/ HER-2/neu complex is internalized efficiently. 27 In this study, we coupled both monoclonal antibodies to the cationic lipid SAINT/DOPE in order to target the lipoplexes to different tumor cells. We assayed the binding of the SAINT/DOPE-MoAb lipoplexes to cells expressing MOC31 or HER-2/neu and investigated if linking SAINT/DOPE to these antibodies influenced the transfection efficiency of the vector.
Material and methods

Cell lines
The murine melanoma cell lines B16F10, the EGP-2-cDNA-transfected B16 melanoma B16C215, and the human breast cancer cell line SKBR-3 were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS (v/v), 2 mM L-glutamine and gentamycin (50 mg/ml) at 371C, 5% CO 2 . The human colon carcinoma HT29 was cultured at 371C, 5% CO 2 in RPMI 1640 supplemented with 15% FCS, 5 Â 10 À5 bmercaptoethanol, 1 mM sodiumpyruvate, and 50 mg/ml gentamycin.
Plasmid DNA and cationic lipids
The plasmid pEGFP-N1 containing the gene encoding for the Green Fluorescent Protein under the control of the CMV promoter was obtained from Clonetech. Plasmid DNA was purified with the Maxi purification kit from Qiagen. SAINT/DOPE (SAINT mix, cat. no. SM-1001) was obtained from Synvolux Therapeutics B.V. (Groningen, the Netherlands). Fugene was purchased from Boehringer Mannheim (cat. no 1815091), and Effectene (cat. no. 3011425) and Superfect (cat. no. 301305) from Qiagen. Transfections were performed according to the companies' instructions. In all experiments, 1 mg DNA was used for transfection and different ratios DNA:carrier were tested if suggested by the company. The DNA:carrier ratio that gave the best transfection results were used in the experiments in which the different reagents were compared with each other.
Transfection protocol SAINT/DOPE
The cells were plated in six-well plates and cultured for 24 hours after which they were transfected at 60-70% confluence. Lipoplexes were made as follows: 1 mg DNA was dissolved in 100 ml Hepes buffered saline (HBS: Hepes 7.5 mM, NaCl 150 mM, pH 7.4) and 15 nmol SAINT/ DOPE was also dissolved in 100 ml HBS. The SAINT solution was added to the DNA, mixed, and after 5 min the volume was adjusted to 1 ml with a serum-free medium. After 15 min, the complexes were added to the cells, which had been washed with HBS. After 4 hours at 371C the volume in the wells was completed up to 2 ml with a serum-containing medium. After 24 hours, the cells were assayed for eGFP expression by FACS (Epics Elite, Beckman Coulter, Miami).
Antibodies
For targeting experiments two monoclonal antibodies were used, MOC31 and Herceptin. The Hospital Pharmacy, University Hospital Groningen kindly provided Herceptin. The mouse monoclonal antibody MOC31 was produced in our laboratory and recognizes the antigen EGP-2 present on carcinoma cell lines. This antibody was purified from a serum-free hybridoma supernatant by a recombinant protein A column (Prosep A high capacity, Millipore BV). F(ab')2 fragments of MOC31 were obtained by enzymatic cleavage of the monoclonal antibody (MoAb) by ficin. 28 To this end, the MoAb was dialyzed against 50 mM Tris containing 2 mM EDTA, pH 7.0. Ficin (1 mg/ml; Sigma Aldrich cat. nr. F4125) was dissolved in Tris/EDTA. Ficin suspension Targeted gene delivery J van Zanten et al was added to the MoAb in a ratio of 1:30 (enzyme:substrate). Enzymatic cleavage was activated by L-cystein (1 mM). The reaction mixture was incubated during 7 hours at 371C. Reactivity was stopped by adding 100 mM N-ethylmaleimide 1:10 (v/v). After cleavage, the antibody mixture was dialyzed against PBS and then the Fc fragment was separated from the F(ab 0 )2 fragment by size-exclusion chromatography (Sephadex G75, Amersham Pharmacia) and stored in PBS.
Preparation of antibody-SAINT/DOPE
The coupling of the monoclonal antibodies (MoAbs) to SAINT was performed by means of the linker molecules SATA (N-succinimidyl S-acetylthioacetate; Pierce 26102)) and SMCC (sulfosuccimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate; Pierce 22322) to introduce a sulfhydryl group into the protein and a maleimide group into the DOPE lipid, respectively.
The antibody or F(ab 0 ) 2 fragment was dissolved at a concentration of 2 mg/ml in PBS. A volume of 10 ml of the SATA solution (65 mM) was added to each milliliter of protein solution and reacted for 30 minutes at room temperature. The modified protein was separated from unreacted SATA by dialysis against PBS containing 1 mM EDTA. Before coupling to the cationic lipid, the SATA-groups were deprotected by hydroxylamine hydrochloride (Pierce 26103). To this end, to each milliliter of the SATA-modified protein solution 100 ml of 0.5 M hydroxylamine hydrochloride in PBS was added and allowed to react for 2 hours. The sulfhydryl-modified protein was purified by dialysis against PBS containing 1 mM EDTA, pH 7.5. The number of introduced sulfhydrylgroups was determined using Ellmans reagent.
SAINT/DOPE was coupled to sulfo-SMCC in three molar ratios. SMCC reacts with the free aminogroup of DOPE and the molecules are linked in a molar ratio (SMCC:DOPE) of 1 : 100, 1 : 500, and 1 : 1000. SAINT/ DOPE (0.75 mM) was reacted with aliquots of sulfo-SMCC (1 mM in PBS) and allowed to react for 1 h at room temperature with gentle mixing. After 1 hour the SMCC linked SAINT/DOPE complex was added to the SATA-linked monoclonal antibody in a ratio of 1 : 1 SMCC: SATA and left overnight at 41C to react. The formed conjugate was used for further experiments without further purification.
Ellman's assay
Ellman's reagent (5, 5 00 -dithiobis(2-nitrobenzoic acid); Pierce cat.nr 22582) reacts with sulfhydryl groups under slightly alkaline conditions to release the highly chromogenic compound 5-thio-2-nitrobenzoic acid (TNB). This compound is used in the assessment of conjugation procedures using sulfhydryl-reactive cross-linking agents. Consequently, the number of SATA molecules linked to the monoclonal antibodies were determined using this assay according to the companies' instructions.
Particle size measurement
The size of the MOC31-SAINT/DOPE complexes with and without DNA was measured with a Nicomp 380/ZLS apparatus from Particle Sizing Systems, Inc. (Santa Barbara, USA). To this end, 7.5 mg DNA was complexed with 150 ml MOC31-SAINT/DOPE and after 5 minutes diluted up to 350 ml with HBS. In this volume, the vesicle size of the complexes was determined.
Binding assay to target cells
To test whether the monoclonal antibodies that had been linked to the SAINT-DOPE cationic lipid were still able to bind to its antigen, the Herceptin-SAINT/DOPE complexes were incubated with the SKBR-3 cells and the MOC31-SAINT/DOPE complexes were incubated with the HT29 cells. As a positive control, the unmodified monoclonal antibodies were used. Cells were incubated with 2 mg antibody as such or conjugated with the SAINT/DOPE complexes for 1 h at room temperature, washed and incubated with an FITC-labeled secondary antibody. For Herceptin Mouse anti-Human (Sigma F5016) was used and for MOC31 Rabbit anti-Mouse (DAKO F0313). Binding to the cells was assayed by FACS analysis.
Binding assay to a mixture of cells
In order to test the in vitro targeting capacity of the monoclonal (MoAb)-labeled SAINT complexes, the complexes were allowed to bind to antigen-expressing cells in a mixture of cells with and without antigen expression. For this purpose, 1 : 1 cell:cell ratio mixtures of B16C215 (expressing EGP-2) and B16F10 cells were used for the MOC31-lipoplexes, and SKBR-3 (expressing HER2/neu) and B16F10 cells were used for the Herceptinlipoplexes. To visualize the binding of the MoAb-SAINT/ DOPE complexes to cells, these complexes were stained with the dye Dil (Molecular Probes, D282) prior to incubation with the cells. Dil integrates into the vesicles formed by SAINT/DOPE. Staining with this label was performed for 2 hours at a final concentration of 0.1 mg/ ml of Dil after which the now labeled MOC31-SAINT/ DOPE complexes were added to the cells. The same concentrations of complexes (15 nmol) and of DNA (1 mg) were used in order to mimic transfection experiments, and after four hours incubating in a medium without serum, a serum-containing medium was added. After a total of 5 hours of incubation, the cells were removed from the plate to detect the binding of the MoAb-SAINT/DOPE complexes. To detect the binding of the MoAbs to the cells incubation was carried out with FITC-labeled, antihuman antibody for Herceptin (Sigma F5016) or antimouse antibody (DAKO F0313) for MOC31. After staining for 1 hour, the cells were analyzed by FACS for the presence of Dil and FITC.
Transfection with MoAb-SAINT/DOPE complexes
The cells were plated in six-well plates and transfected at 60-70% confluence. For transfection experiments with Herceptin-DOPE/SAINT SKBR-3 cells were used, and for experiments with MOC31-SAINT/DOPE HT29 cells and B16C215 were used. As a control for a non-target cell line, B16F10 cells were used. Lipoplexes were made as follows: 1 mg of DNA was dissolved in 100 ml Hepes buffered saline (HBS) and was added to 15 nmol MoAb-SAINT/DOPE. After 5 minutes, the volume was adjusted to 1 ml with a serum-free medium. After 15 minutes, the complexes were added to the cells which had been washed with HBS. After 4 hours at 371C another 1 ml serumcontaining medium was added and after 24 hours the cells were assayed for eGFP expression.
16,18
Results
Transfection with different reagents
In order to relate the transfection rate of SAINT/DOPE with other transfection reagents, four different cell lines were transfected with SAINT/DOPE, Effectene, Fugene, or Superfect. The cell lines used were the mouse melanoma cell line B16F10, the human colon carcinoma cell line HT29, the mouse endothelial cell line H5V, the human epithelial cell line HEp2, and the human Burkitt's lymphoma cell line RAMOS. The cells were transfected with the plasmid pEGFP-N1 containing the gene encoding for the Green Fluorescent Protein. Transfection experiments were performed according to the company's instructions and if suggested, different ratios of DNAtransfection reagents were tested first. After determination of the optimal ratios, the transfection experiments were performed and the results were compared to each other. In these experiments, 1 mg DNA was used in combination with 15 ml SAINT, 20 ml Effectene, 3 ml Fugene, or 5 ml Superfect. One day after transfection, eGFP expression of the transfected cells was assayed by FACS. All experiments were performed three times. The results of optimal DNA/transfection compound are shown in Table 1 . It was found that the transfection reagents gave consistent results in the three performed experiments. The cell lines B16F10 and Hep2 were easier to transfect than the cell lines HT29 and H5V. It was seen that especially in those cell lines that gave low number of transfected cells, SAINT/DOPE had the highest number of transfected cells. With respect to the values of mean intensity per cell, no differences were found for the different reagents in the cell lines B16F10, HT29 and H5V. However, it was noticed that Fugene gave a lower amount of transfected cells in the HEP-2 cell line, but the mean intensity of these transfected cells almost doubled compared to the mean intensity per cell found for the SAINT/DOPE complexes.
Coupling of monoclonal antibodies to SAINT/DOPE
The coupling of the monoclonal antibodies (MoAbs) MOC31 and Herceptin to SAINT/DOPE was established by using the cross-linker molecules SATA and SMCC that contain amine-and sulfhydryl-reactive groups, respectively. The monoclonal antibodies (MoAbs) Herceptin and MOC31 were linked to SATA. The degree of ÀSH modification was determined by an Ellman's assay and it was shown that by using a 10 molar excess SATA concentration, three SATA molecules were linked to one MOC31 molecule and five SATA molecules were linked to one Herceptin molecule. This was a consistent finding for several coupling experiments. The second linker molecule SMCC was linked to DOPE of the SAINT/ DOPE (1 : 1) mixture. The thiolated MoAb and DOPE/ SAINT with the maleimide group were conjugated by mixing both modified molecules. The different molar ratios of monoclonal antibody to DOPE used were 1 : 100, 1 : 500, and 1 : 1000. 
In all experiments 1 mg DNA is used. The results represent the absolute number of transfected cells expressing the eGFP protein as assayed by FACS analysis. The mean of three experiments is given with standard deviation. The target cell line for MOC31 is HT29 (expressing EGP-2), the target cell line for Herceptin is SKBR-3 (expressing the Neu/her2 antigen). The cell line B16F10, used as a negative control, expresses neither of both antigens. In all samples, the same amount of monoclonal antibody is used, i.e. 2 mg. Values of the mean intensity per cell (MFI) are given.
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After coupling the antibodies to the DOPE/SAINT lipids, we tested whether the cross-linked monoclonal antibodies were still able to recognize their antigen. Binding of MOC31-SAINT/DOPE complexes to B16C215 cells that express the antigen EGP-2 was investigated by flow cytometry as well as binding of anti-Herceptin SAINT/DOPE complexes to SKBR-3 cells overexpressing Her2/neu. The results showed that the cross-linked MoAbs recognized their epitopes to the same extent as the original MoAbs (Table 2) . Both cross-linked MoAbs did not bind to B16F10 cells that did not express EGP-2 or Her2/neu.
The particle size of the SAINT/DOPE and the MOC31-SAINT/DOPE complexes with and without DNA were determined. The results are shown in Table 3 .
Binding of MoAb-SAINT:DOPE to target cells
To demonstrate the specificity of binding of the targeted constructs, lipoplexes were incubated with mixed cell populations consisting of target and nontarget cells. The assay resembled a transfection experiment, but here SAINT/DOPE complexes were stained with the fluorescent dye Dil and the antibody bound to the cell membranes was traced with secondary antibody recognizing the monoclonal antibody. Binding was evaluated by FACS analysis after 5 hours of incubation.
In Figure 1 , the binding of MOC31-DOPE/SAINT is shown. B16C215 cells were used as target cells for MOC31 and these cells were mixed with B16F10 that do not express the antigen EGP2. It appeared that the MOC31-SAINT/DOPE complexes bind less or to the same extent as the original SAINT/DOPE complexes to the nontarget cells, B16F10. SAINT/DOPE complexes with the highest number of antibody (ratio 1 : 100) bind less efficiently to both cell types in the mixed cells. By cross-linking less monoclonal antibody to the cationic lipid (ratios 1 : 500 and 1 : 1000) the binding improves to up to 15% of the target cells, while the binding to the nontarget cells remains unaffected. In Figure 1 (right graph), the binding of Herceptin-DOPE/SAINT is shown. In these experiments SKBR-3 cells were used as target cells. Similar to the results with MOC31 lipoplexes, Herceptin-SAINT/DOPE complexes hardly bind to nontarget cells, and show comparable binding or less as seen for the SAINT/DOPE complexes without antibody. Interestingly, we observed specific binding to the Her2/ neu cells by the Herceptin-SAINT/DOPE complexes, especially in the ratios 1 : 500 and 1 : 1000. The binding of the Herceptin-SAINT/DOPE complexes exceeds 4-6 times the binding of SAINT/DOPE to the SKBR3 cells. This strongly suggests that targeting can be realized by cross-linking a monoclonal antibody to a transfection reagent.
The statistical significance of the binding to the target cell lines compared to the binding to the nontarget cell line B16F10 was determined. To this end, the ratio of binding of the MoAb-SAINT/DOPE complexes to target cell lines was related to the binding of these complexes to nontarget cell lines. Figure 2 shows the 95% confidence intervals calculated for the different complexes. This figure illustrates that the binding of MOC31-SAINT-DOPE and of Herceptin-SAINT-DOPE complexes is significantly higher to target cells than to nontarget cells. Measurements were performed with the native SAINT/DOPE complexes with and without DNA and also after covalent attachment with MOC31 (MOC31-SAINT/DOPE). Three ratios of MOC31-SAINT/DOPE and Herceptin-SAINT/DOPE were assayed; 1 : 100, 1 : 500, and 1 : 1000. It is shown that MOC31-SAINT/DOPE as well as Herceptin-SAINT/DOPE lipoplexes bind to a higher extent to the target cells than to the nontarget cells.
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Binding of the MoAb-SAINT/DOPE lipoplexes to the target cells could be substantially blocked in a competitive inhibition experiment. Target cells SKBR-3 and HT29 were preincubated for 2 hours with Herceptin and MOC31, respectively. Subsequently, the cells were incubated with the MoAb-SAINT/DOPE complexes in the ratios 1 : 500 and 1 : 1000. After 5 hours, binding was analyzed by FACS and compared to binding to target cells that had not been preincubated with monoclonal antibodies. The binding with Herceptin-SAINT/DOPE to SKBR-3 cells reduced after preincubation from 35 to 15% (reduction of 57%) in ratio 1 : 500 and from 58 to 32% (reduction of 45%) in the 1 : 1000 ratio. For MOC31-SAINT/DOPE, the reduction rates were 50% (from 8 to 4%) and, 57% (from 14 to 6%), respectively.
Transfection of SAINT-DOPE linked to an antibody
In order to determine if MoAb-coupled SAINT/DOPE lipoplexes could improve gene expression, transfection experiments were performed with SAINT/DOPE alone and with SAINT/DOPE coupled to the antibodies MOC31 and Herceptin. First, the MoAbs were coupled to the SAINT/DOPE and then the DNA was complexed with the lipid. When the DNA was complexed before the chemical linking of the monoclonal antibodies to SAINT/ DOPE was performed, no transfection of cells was observed (data not shown). Different ratios of DNAcomplexes were tested in transfection experiments in order to determine the best ratio DNA:MoAb-SAINT/ DOPE. Transfection experiments were performed using 1 mg DNA (vector containing the eGFP plasmid) complexed with 7.5, 15, and 22.5 nmol SAINT/DOPE. The SAINT/DOPE complexes linked with antibody or without antibody were both assayed in transfection experiments using these ratios. It appeared that for antibodylinked complexes the best transfection rates were obtained using 1 mg DNA complexed with 15 nmol SAINT/DOPE, which is similar as used for the original SAINT/DOPE Figure 2 Statistical significance of the preferential binding of MoAb-SAINT/DOPE to their target cells is given compared to the nontarget cells. The rate of binding of the lipoplexes to the target cells is determined in relation to the binding to the nontarget cells. This was done for the results found in three experiments and of the three different coupling ratios MoAb-SAINT/DOPE (1 : 100, 1 : 500, and 1 : 1000). The found values were log transformed after which the mean, the standard deviation, standard error of the mean, and the 95% confidence interval were determined. The bar represents the 95% confidence interval and the square the mean. It was found that for all ratios the 95% confidence interval was above the line Y ¼ 1, which means that the binding of both MoAb-SAINT/DOPE lipoplexes is significantly higher to the target cell lines than to the nontarget cell line B16F10. Targeted gene delivery J van Zanten et al complexes. These ratios were further used in the transfection experiments of the cell lines B16C215, SKBR-3, and B16F10. Figure 3 shows that the transfection efficiency of SAINT-DOPE lipoplexes linked to MOC31 is comparable to the lipoplexes without antibody. The ratio 1 : 100 (highest antibody ratio) gave low transfection results, which is in agreement with the low binding of these lipoplexes in the previous binding experiments. The ratio 1 : 1000 gave the highest transfection rates in the target cell line HT29 that is positive for EGP-2. Transfection of this cell line by SAINT/DOPE lipoplexes resulted in about 20% transfected cells, but could be enhanced by using MOC31-SAINT/DOPE lipoplexes up to a transfection efficiency of 32%. However, this was not a consistent finding. Transfecting the second target cell line B16C215 with MOC31-SAINT/ DOPE was never higher compared to the original SAINT/ DOPE complexes. Herceptin-SAINT/DOPE lipoplexes in the ratios 1 : 500 and 1 : 1000 consistently gave higher transfection results than the original SAINT/DOPE lipoplexes. The transfection efficiency was doubled in one experiment but mostly was enhanced from 50% (using the native SAINT/DOPE complexes) to 70% transfected cells by using the Herceptin-SAINT/DOPE lipoplexes. This confirmed the results found in the binding experiments, where also higher levels of binding were seen for Herceptin than for MOC31-linked lipoplexes.
We determined if these results were due to a higher expression level of HER-2/neu than EGP-2 on the target cells. The mean fluorescence intensity (MFI) of B16C215 cells by staining with MOC31 was the lowest (100-200), the MFI of HT29 after staining by MOC31 was about 500-600, and the MFI of SKBR-3 after staining with Herceptin was the highest with an MFI of about 1000. So the better binding and transfection of Herceptin-DOPE/ SAINT lipoplexes to the target cells compared to the MOC31-SAINT/DOPE binding can also be due to a higher expression of the HER-2/neu antigen.
Preparation and binding of F(ab')2 fragments
The same experiments were performed using F(ab 0 )2 fragments of the monoclonal antibody MOC31. First fragments were made using the enzyme pepsin. However, this cleaved the mouse antibody (subclass IgG1) completely (data not shown). Alternatively, ficin was used, which has been described to give high-yield active bivalent fragments from mouse IgG1. 28 The procedure gave satisfactory results with a yield of 30% and a stable F(ab 0 )2 fragment. The F(ab 0 )2 fragments were used for cross-linking with SAINT/DOPE using the same molar amount of SATA molecules as has been described for the MOC31 antibody. Ellman's assay showed that the average number of SATA molecules bound to one F(ab 0 )2 fragment was 6. Binding experiments and transfection experiments were performed similarly as described for MoAb-SAINT/DOPE lipoplexes. A mixture of B16F10 and B16C215 cells were used in the binding experiment and transfection was performed in the HT29 cell line and B16C215 cell line. These experiments demonstrated that the binding as well as the transfection efficiency of SAINT/DOPE complexed with the F(ab 0 )2 fragments of MOC31 gave comparable results as found with the complete antibody MOC31. This shows that targeting can be achieved by only using the antigen binding part of a monoclonal antibody. The results of a binding and a transfection experiment are shown in Figure 4 .
Discussion
We have shown in this study that, compared to other known transfection reagents, SAINT is a well-competing transfection reagent for in vitro use, capable of giving high transfection efficiency in cells. Especially transfecting the H5 V and Hep2 cell lines SAINT gave superior results. Nonadherent cell lines could not be transfected with these reagents. This confirms the general idea that it is still difficult to transfect cell lines growing in suspension using nonviral transfection reagents. Our results confirm that 16, 17 This makes SAINT/DOPE a good candidate for further improvement for in vitro and possibly for in vivo use. However, in contrast to the in vitro transfection rates, the general in vivo transfection rate of nonviral reagents is still far lower than the viral vectors used so far. In order to improve in vivo transfection and reduce nonspecific transfection, we hypothesized that linking SAINT with a monoclonal antibody (or derivatives thereof) could improve transfection. We used the monoclonal antibodies (MoAbs) MOC31 and Herceptin as targeting moieties. Our results showed that these MoAbs could be linked successfully to SAINT/DOPE complexes by covalent attachment under nonreducing conditions. The coupling procedure we used gave consistent results in several experiments and did not affect the binding properties of the MoAbs. The MoAb-SAINT/DOPE complexes were stable for at least 2 months (data not shown). As shown in the binding experiments, binding was enhanced to tumor target cells in a mixed cell culture using MoAb-SAINT/ DOPE lipoplexes, especially when targeted with Herceptin. The Herceptin-linked SAINT/DOPE also gave consistently higher transfection rates in cell lines expressing Neu/her2 but not to the same exent as the difference in binding. This can be explained by the fact that transfection is also, and possibly largely, determined by the biological properties of the lipoplex. So, the results obtained with Herceptin-SAINT/DOPE seemed to be better than with MOC31-SAINT/DOPE. We think that the difference in binding cannot be explained alone by a lower expression of the antigen EGP-2 on the membrane of the cell because the expression of EGP-2 was about half the expression of Herceptin on the cell lines used. The fact that Herceptin-linked carriers gave better transfection than MOC31-linked carriers might also be due to the fact that neu/HER2 is an internalizing epitope, 27 while EGP2 possibly internalizes slowly. 29 It has been shown that the binding of radiolabelled MOC31 can be traced for at least 3 days in vivo. This suggests that targeting to a fast internalizing epitope such as HER2/neu will result in an uptake that leads to a higher transfection efficiency. However, whether this is due to the rate of internalization itself or due to another intracellular route after the lipoplex has been internalized is speculative and needs further investigation. Such a different route might lead to lower breakdown of DNA. Most likely, endocytosis represents the main route of cellular entry pathway for lipoplexes, but the exact route of endocytic internalization as well as the mechanism of plasmid escape from the endosome remains to be determined.
Also the size of the complex influences the uptake by the cells. When the monoclonal antibody was linked in a molar ratio of 1 : 100 to the SAINT-DOPE complex no or very low transfection rates were found. Low transfection was not due to toxic effects because the use of the 1:100 ratio had no effect on the viability of the cells. Presumably, it is due to the size of the complex. By measuring the size of the complexes it was seen that these complexes were ten times larger than the other complexes.
SAINT/DOPE without DNA is about 400 nm but complexed with DNA and linked with antibody in a 1 : 100 ratio complexes are formed with a size of about 12 mm. The other MoAb-SAINT/DOPE ratios resulted in complexes of about 2 mm. Ross et al 30 have shown before that lipoplexes with a size up to 2.5 mm were taken up quite efficiently by cells, even better than smaller complexes. They found that size increase had a major effect on the uptake of the complexes, in contrast to differences in net charge. However, we found a wide range in complex size for the ratios 1 : 500 and 1 : 1000. We expect that if we can prepare complexes of 2À3 mm without major size heterogeneity, binding and/or transfection can even be improved.
In the present study, we have shown that targeting of cationic lipoplexes is possible using monoclonal antibodies. For targeting strategies, smaller antibodies with only the antigen-recognizing part and without the Fc tail can be used in order to reduce the undesirable biological properties of the protein. For this purpose, we have made F(ab)2 fragments of the antibody MOC31. We demonstrated that the F(ab 0 )2 fragments can be linked to the SAINT/DOPE complexes in the same proportion as the native antibody and that the SAINT-DOPE-F(ab')2 complexes recognize the target cells to the same extent as complexes prepared with the whole antibody. Even smaller fragments, like single-chain fragments can be used for targeting. Targeting with a single-chain Fv fragment specific for the transferrin receptor has been described by Xu et al. 22 In conclusion, we have shown the potential of the cationic lipid-based device SAINT-DOPE carrier for in vitro transfection. Targeting of the complex using antibodies has been proven in in vitro setting. Together with the fact that in a first study, SAINT/DOPE complexes administered intravenously in moderate doses in mice gave no significant toxic effects, 31 these data are relevant for further application of this cationic lipid as a DNA transfection agent.
